Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 6;8(15):e012943.
doi: 10.1161/JAHA.119.012943. Epub 2019 Jul 26.

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Affiliations

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Yogesh N V Reddy et al. J Am Heart Assoc. .

Abstract

Background Neprilysin is a metalloprotease involved in proteolysis of numerous peptides, including natriuretic peptides, and is of prognostic and therapeutic importance in heart failure with reduced ejection fraction. No studies have investigated circulating neprilysin in the community, its clinical correlates, or its relationship to cardiovascular disease in the general population. Methods and Results Plasma neprilysin was measured in 1536 participants from Olmsted County, Minnesota, using a commercially available sandwich ELISA assay. Clinical and echocardiographic correlates and subsequent outcomes were determined. Soluble neprilysin is non-normally distributed in the community (median: 3.9 ng/mL; interquartile range: 1.0-43.0 ng/mL). There was no relationship between plasma neprilysin and age (Spearman correlation: -0.04, P=0.16); body mass index (Spearman correlation: -0.04, P=0.16); glomerular filtration rate (Spearman correlation: -0.007, P=0.8); or A-, B-, or C-type natriuretic peptides (Spearman correlation: 0.03, P=0.22; -0.001, P=0.96; 0.01, P=0.67, respectively). Among tertiles of neprilysin, the lowest tertile group had the highest prevalence of smokers (P<0.001), hypertension (P=0.04), dyslipidemia (P=0.03), and diastolic dysfunction (P=0.02). Soluble neprilysin was not prospectively associated with death or heart failure over a median of 10.7 years. Conclusions In a large community-based cohort, for the first time, we described the distribution of circulating neprilysin in the general community. We observed that neprilysin does not correlate with natriuretic peptide levels and is not independently associated with adverse outcomes. The novel associations observed between low soluble neprilysin levels and an adverse cardiometabolic and smoking profile requires further investigation.

Keywords: biomarker; diastolic dysfunction; neprilysin; smoking.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scatter plot of age (x‐axis) vs soluble neprilysin (sNEP; y‐axis log scale) by sex. The Spearman correlation coefficients between age and neprilysin were −0.04 overall, −0.04 for male participants, and −0.03 for female participants.
Figure 2
Figure 2
Median soluble neprilysin (sNEP) levels with interquartile ranges according to smoking status among participants. A, Overall. B, Those without any risk factors or cardiovascular disease (normal). C, Nonobese participants. D, Low ejection fraction (EF). E, Moderate/severe (MS) diastolic dysfunction (DD) with normal EF. F, Any DD with normal EF. MMS indicates mild/moderate/severe. P values are derived from the Wilcoxon rank sum test.
Figure 3
Figure 3
Prevalence of smoking, hypertension, and diastolic dysfunction across low, intermediate (Int), and high neprilysin (NEP) tertiles. P values are trend tests for proportions across NEP tertiles.

References

    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K. Zile MR, Investigators P‐H and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. - PubMed
    1. Bayes‐Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68:639–653. - PubMed
    1. Bayes‐Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupon J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–665. - PubMed
    1. Goliasch G, Pavo N, Zotter‐Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail. 2016;18:89–93. - PubMed
    1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202. - PubMed

Publication types